INTELLIGENT BIO SOLUTIONS INC.

Listed Company

INBSCIK 0001725430NasdaqEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Jun 30

Period

FY 2025

Revenue

$3.05M

Net Income

$-10.57M

Total Assets

$8.25M

Equity

$3.00M

Shares Out

1.60M

Op. Cash Flow

$-9.68M

Business

INTELLIGENT BIO SOLUTIONS INC. is a medical technology company that develops and delivers non-invasive, rapid diagnostic and screening solutions based on fingerprint sweat analysis. Its main products include the commercially available Intelligent Fingerprinting Drug Screening System (cartridge and portable reader) and a biosensor platform for point-of-care tests, the latter of which is subject to licensing matters affecting further development. The company reports by four geographic segments—United Kingdom; Asia Pacific; Americas; and Rest of World—and sells via direct sales, distributors and strategic partnerships, with manufacturing in Cambridge, UK.

Summary from filing dated 2025-08-15

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Revenue	3	3	1	—	2
Cost of revenue (exclusive of amortization shown separately below)	−2	−2	−930,204	—	—
Gross profit	1	1	326,668	—	—
Government support income	816,901	424,776	—	—	—
Selling, general and administrative expenses	−9	−9	−8	−5	3
Development and regulatory approval expenses	−2	−2	−507,424	−4	4
Depreciation and amortization	−1	−1	−966,732	—	—
Impairment of long-lived assets	−220,062	—	—	—	—
Total operating expenses	−13	−12	−14	−9	8
Loss from operations	−11	−10	−13	−8	−6
Interest expense	−60,890	−167,140	—	—	—
Realized foreign exchange loss	−911	−1,178	−9,829	−3,987	−271,225
Fair value gain on revaluation of financial instrument	—	175,738	2	—	—
Interest income	101,522	84,822	—	—	—
Total other income, net	39,721	92,242	2	2,900	−1
Net loss	−11	−10	−11	−8	−7
Net loss attributable to non-controlling interest	−36,153	−34,173	−32,835	−27,925	−22,915
Net loss attributable to Intelligent Bio Solutions Inc.	−11	−10	−11	−8	−7
Foreign currency translation gain (loss)	384,670	−137,118	212,639	−126,875	−297,309
Total other comprehensive income (loss)	384,670	−137,118	212,639	−126,875	−297,309
Comprehensive loss	−10	−10	−10	−8	−7
Comprehensive loss attributable to non-controlling interest	−36,153	−34,173	−32,835	−27,925	−22,915
Comprehensive loss attributable to Intelligent Bio Solutions Inc.	−10	−10	−10	−8	−7
Net loss per share, basic	−2	−6.38	−127	−11.33	−0.68
Net loss per share, diluted	−2	−6.38	−127	−11.33	—
Weighted average shares outstanding, basic	5	2	83,717	733,263	10
Weighted average shares outstanding, diluted	5	2	83,717	733,263	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash and cash equivalents	1	6	2	8	13
Accounts receivable, net	594,614	429,704	293,861	—	—
Inventories, net	635,215	777,537	979,907	—	—
Research and development tax incentive receivable	734,408	525,332	498,758	353,048	1
Assets held for sale	327,500	—	—	—	—
Other current assets	826,976	497,572	552,791	746,761	3
Total current assets	4	9	4	11	18
Property and equipment, net	251,325	565,850	690,175	391,408	—
Operating lease right-of-use assets	69,520	306,744	546,475	—	—
Intangibles, net	4	4	5	—	—
Total assets	8	14	10	12	22
Accounts payable and accrued expenses	5	2	3	2	1
Current portion of operating lease liabilities	84,659	274,834	223,447	—	—
Deferred grant income	—	2	2	3	2
Current employee benefit liabilities	534,990	469,381	358,942	201,332	102,475
Notes payable	197,146	515,282	353,211	—	—
Total current liabilities	5	5	6	5	4
Employee benefit liabilities, less current portion	84,921	63,615	24,902	50,626	21,770
Operating lease liabilities, less current portion	—	81,324	356,165	—	—
Total liabilities	5	6	7	6	7
Commitments and contingencies (Note 16)	—	—	—	—	—
Common stock, $0.01 par value, 100,000,000 shares authorized, 7,323,377 and 7,323,261 shares issued and outstanding, as of June 30, 2025, respectively; 3,456,116 and 3,456,000 shares issued and outstanding, as of June 30, 2024 respectively	73,230	34,557	1,942	7,445	135,821
Treasury stock, at cost, 116 shares as of June 30, 2025 and 2024	−1	−1	−1	—	—
Additional paid-in capital	66	61	46	39	38
Accumulated deficit	−63	−52	−42	−31	−23
Accumulated other comprehensive loss	−327,944	−712,614	−575,496	−788,135	−661,260
Total consolidated Intelligent Bio Solutions Inc. equity	3	8	4	7	15
Non-controlling interest	−182,312	−146,159	−111,986	−79,151	−51,226
Total shareholders equity	3	8	4	7	15
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	8	14	10	12	22

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Depreciation and amortization	970,117	974,355	814,481	—	—
Amortization of right-of-use assets	243,632	238,730	152,251	—	—
Non-cash loss on foreign currency translation, net	—	1,178	9,829	−3,987	—
Provision for credit losses	546	6,772	—	—	—
Provision for inventory obsolescence	—	69,676	189,670	—	—
Stock-based compensation	238,045	230,496	260,000	—	—
Non-cash refund of R&D expenditure claims	−137,696	—	—	—	—
Fair value gain on revaluation of holdback Series C Preferred Stock	—	−175,738	−616,800	—	—
Non-cash other operating activities	113,645	−24,177	−94,332	−8,179	−66,055
Accounts receivable	−164,910	−135,843	−293,861	—	—
Inventories	142,322	202,370	−345,390	—	—
Grant receivable / deferred grant income	−2	148,611	1	2	—
Research and development tax incentive receivable	−209,076	−26,574	−145,710	672,407	−1
Other current assets	−329,404	55,219	−118,335	−333,743	−2
Accounts payable and accrued expenses	3	−632,950	—	—	—
Long-term employee benefit liabilities	21,306	−364,149	—	28,856	21,770
Operating lease liabilities	−271,499	51,387	−107,922	—	—
Net cash used in operating activities	−10	−10	−7	−3	−11
Purchase of property and equipment	−231,838	−221,426	—	—	—
Net cash used in investing activities	−231,838	−221,426	−694,142	−880,221	—
Proceeds from issuance of common stock and warrants, net of issuance costs	5	4	3	—	—
Proceeds from exercise of warrants, net of issuance costs	7,939	2	—	—	—
Proceeds from private placement, net of issuance costs	—	9	—	—	—
Net cash provided by financing activities	5	15	1	—	23
Effect of foreign exchange rates on cash and cash equivalents	27,157	−707	−64,860	−97,129	39,971
Net decrease (increase) in cash and cash equivalents	−5	5	−7	−4	12
Equity issuance costs in accounts payable and accrued expenses	14,999	—	—	—	—
Conversion of preferred shares into common shares	—	57,287	36,888	13,000	45,102
Conversion of holdback Series C Preferred Stock into common stock	—	32,762	—	—	—
Issuance of common stock upon cashless exercise of Series F warrants	55	6,551	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro